These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31004363)

  • 1. New potentials for 3-hydroxy-3-methyl-glutaryl-coenzymeA reductase inhibitors: Possible applications in retarding diabetic complications.
    Bahrambeigi S; Rahimi M; Yousefi B; Shafiei-Irannejad V
    J Cell Physiol; 2019 Nov; 234(11):19393-19405. PubMed ID: 31004363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications.
    Nabi R; Alvi SS; Saeed M; Ahmad S; Khan MS
    Curr Diabetes Rev; 2019; 15(3):213-223. PubMed ID: 30246643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulatory role of HMG-CoA reductase inhibitors and ezetimibe on LDL-AGEs-induced ROS generation and RAGE-associated signalling in HEK-293 Cells.
    Nabi R; Alvi SS; Shah A; Chaturvedi CP; Iqbal D; Ahmad S; Khan MS
    Life Sci; 2019 Oct; 235():116823. PubMed ID: 31476307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end products and diabetic complications: a general overview.
    Peppa M; Vlassara H
    Hormones (Athens); 2005; 4(1):28-37. PubMed ID: 16574629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for diabetic cardiovascular complications.
    Ludwig S; Shen GX
    Curr Vasc Pharmacol; 2006 Jul; 4(3):245-51. PubMed ID: 16842142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin therapy for the treatment of diabetic dyslipidemia.
    Haffner SM
    Diabetes Metab Res Rev; 2003; 19(4):280-7. PubMed ID: 12879405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of lipids in the development of diabetic microvascular complications: implications for therapy.
    Misra A; Kumar S; Kishore Vikram N; Kumar A
    Am J Cardiovasc Drugs; 2003; 3(5):325-38. PubMed ID: 14728067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
    Ginsberg HN
    J Clin Endocrinol Metab; 2006 Feb; 91(2):383-92. PubMed ID: 16291700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it time to reconsider combination lipid therapy in high-risk diabetic patients?
    Blood AJ; Krasuski RA
    Curr Opin Lipidol; 2016 Jun; 27(3):310-1. PubMed ID: 27145105
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of diabetic dyslipoproteinemia.
    Steinmetz A
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2019)].
    Wascher TC; Paulweber B; Toplak H; Saely CH; Drexel H; Föger B; Hoppichler F; Stulnig T; Stingl H; Clodi M;
    Wien Klin Wochenschr; 2019 May; 131(Suppl 1):136-138. PubMed ID: 30980157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel inhibitors of glycation and AGE formation.
    Rahbar S
    Cell Biochem Biophys; 2007; 48(2-3):147-57. PubMed ID: 17709884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylglyoxal, a potent inducer of AGEs, connects between diabetes and cancer.
    Bellier J; Nokin MJ; Lardé E; Karoyan P; Peulen O; Castronovo V; Bellahcène A
    Diabetes Res Clin Pract; 2019 Feb; 148():200-211. PubMed ID: 30664892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
    Calkin AC; Allen TJ
    Am J Cardiovasc Drugs; 2006; 6(1):15-40. PubMed ID: 16489846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.
    Brings S; Fleming T; Freichel M; Muckenthaler MU; Herzig S; Nawroth PP
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28475116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular death, reactive oxygen species (ROS) and diabetic complications.
    Volpe CMO; Villar-Delfino PH; Dos Anjos PMF; Nogueira-Machado JA
    Cell Death Dis; 2018 Jan; 9(2):119. PubMed ID: 29371661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?].
    Parhofer KG
    Herz; 2016 May; 41(3):217-23. PubMed ID: 26961236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.